Document:

Exhibit 10.1

 

LOAN AGREEMENT

 

This Loan Agreement
(this “Agreement”), dated effective May 1, 2016, is by and between Creative Medical Technologies, Inc., a Nevada
corporation (the “Borrower”), and Creative Medical Health, Inc., a Delaware corporation (the “Lender”).
The Lender and the Borrower will be individually referred to as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, the Borrower
entered into a Loan Agreement dated February 2, 2016, under which the Borrower borrowed $50,000 from the Lender prior to the effective
date of this Agreement (the “Original Loan Agreement”);

 

WHEREAS, the Borrower
has indicated that it wishes to borrow up to an additional $50,000 through a series of loan advances (each a “Loan Advance”)
by the Lender to the Borrower as provided herein; and

 

WHEREAS, the Parties
desire that the Lender will loan the Borrower money to be used to continue to launch the proposed business of the Borrower.

 

NOW THEREFORE, in consideration
of the foregoing recitals, mutual covenants contained herein, and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereby agree as set forth below.

 

1.          Loan
of Funds. In one or more Loan Advances, the Lender shall loan to the Borrower $50,000.00 (the “Loaned Funds”).
The Loan Advances shall be made by the Lender upon written request of the Borrower and based upon the availability of funds by
the Lender. The rights of the parties in the Loaned Funds and the terms under this Agreement and the Original Loan Agreement shall
be pari pasu and neither loan shall be senior, or grant rights superior, to the other loan.

 

2.          Principal.
Upon receipt of funds from the Lender, the Borrower promises unconditionally to pay to the order of the Lender the aggregate principal
amount of the Loaned Funds represented by each Loan Advance, together with interest pursuant to this Agreement and the corresponding
promissory note documenting the Loan Amount. Repayment of the Loan Amount shall be subject to the terms and conditions of the 8%
Promissory Note attached hereto as Exhibit 1 (the “Note”).

 

3.          Interest
Rate. The rate of simple interest for the Loan Amount shall be 8% per annum and will be due as provided in the Note. The Note
will be due as set forth therein (the “Maturity Date”). Interest shall be calculated on the basis of a year
of 365 days applied to the actual days on which there exists an unpaid balance under the Note. Interest on the Note shall be payable
on the Maturity Date. In addition, the Borrower shall repay the entire principal of the Loan Amount as well as all accrued interest
according to the terms of this Agreement and the Note on the Maturity Date.

 

4.          Retroactive
Effectiveness. This Agreement shall be effective retroactive to May 1, 2016, and shall be binding upon any funds advanced by
CMH since that date as provided in this Agreement.

 

5.          Representations
and Warranties.

 

The Borrower represents
and warrants to the Lender as follows:

  

     

     

    

 

5.1           Powers
and Authority. The Borrower has all necessary power to carry on its present business and has full right, power and authority
to enter into this Agreement, to make the borrowings herein provided for, and otherwise perform and to consummate the transactions
contemplated hereby.

 

5.2           No
Conflicts. This Agreement does not, and the performance or observance by the Borrower of any of the matters and things herein
provided for will not, constitute an event of default, or event which with the lapse of time, the giving of notice or both, would
constitute an event of default under any agreement to which it is a party or by which it is bound.

 

5.3           Corporate
Organization. The Borrower is a duly organized and validly existing under its jurisdiction of organization.

 

5.4           Corporate
Authorization. The board of directors of the Borrower has authorized the execution and performance of this Agreement.

 

6.         Successors
and Assigns; Assignment.  Except as otherwise expressly provided herein, the provisions hereof inure to the benefit
of, and be binding upon, the successors, assigns, heirs, executors and administrators of the Parties hereto.  Nothing
in this Agreement, express or implied, is intended to confer upon any party, other than the Parties hereto and their successors
and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
herein.  The Borrower may not assign this Agreement or any of the rights or obligations referenced herein without the
prior written consent of the Lender. The Lender may assign this Agreement, in whole or in part, without the prior consent of the
Borrower, and any assignee of this Agreement shall inure to all of the rights of the Lender hereunder.

 

7.         Default
Notice. Upon the occurrence of a breach of this Agreement, the defaulting party is entitled to receive written notice specifying
the breach. Such notice shall be sent immediately upon discovery of the breach. The defaulting party shall then be entitled to
30 days in which to cure the problem. Events of Default are defined in the Note, which is incorporated herein by this reference.

 

8.         Rights
and Remedies upon Default. Upon the occurrence of an Event of Default the Lender (acting upon the written instruction and at
the direction of the Required Majority, as defined in the Security Agreement) may exercise any and all rights and remedies available
in the Notes and the Security Agreement, and available in law, in equity or otherwise.

 

  9.         Heading;
References.  All headings used herein are used for convenience only and shall not be used to construe or interpret
this Agreement.  Except as otherwise indicated, all references herein to Sections refer to Sections hereof.

 

10.         Binding
Agreement; Survival. This Agreement shall bind and inure to the benefit of both parties, and except as otherwise expressly
provided to the contrary herein, each of their respective heirs, successors and assigns.

 

11.         Delays
or Omissions. No delay or omission to exercise any right, power, or remedy accruing to the Lender, upon any breach or default
of the Borrower under this Agreement shall impair any such right, power, or remedy of the Lender nor shall it be construed
to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter
occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or
thereafter occurring. All remedies, either under this Agreement or by law or otherwise afforded to the Lender, shall be cumulative
and not alternative.

 

    	2 

     

    

  

12.         Construction.
The parties acknowledge that the parties and their counsel have reviewed and revised this Agreement and that the language used
in this Agreement has been chosen by the parties to express their mutual intent. Accordingly, no rules of strict construction will
be applied against any party with respect to this Agreement.

 

13.         Cumulative
Rights. No delay on the part of the Lender in the exercise of any power or right under this Agreement or under any other instrument
executed pursuant to this Agreement shall operate as a waiver of any such power or right, nor shall a single or partial exercise
of any power or right preclude other or further exercise of such power or right or the exercise of any other power or right.

 

14.         Payments
Free of Taxes, Etc. All payments made by the Borrower under this Agreement shall be made by the Borrower free and clear
of and without deduction for any and all present and future taxes, levies, charges, deductions, and withholdings. In addition,
the Borrower shall pay upon demand any stamp or other taxes, levies or charges of any jurisdiction with respect to the execution,
delivery, registration, performance, and enforcement of this Agreement. Upon request by the Lender, the Borrower shall furnish
evidence satisfactory to the Lender that all requisite authorizations and approvals by, and notices to and filings with, governmental
authorities and regulatory bodies have been obtained and made and that all requisite taxes, levies, and charges have been paid.

 

15.         Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision(s) shall be excluded
from this Agreement and the balance of this Agreement shall be interpreted as if such provision(s) were so excluded and shall be
enforceable in accordance with its terms.

 

16.         Other
Interpretive Provisions. References in this Agreement to any document, instrument or agreement (a) includes all exhibits, schedules,
and other attachments thereto, (b) includes all documents, instruments or agreements issued or executed in replacement thereof,
and (c) means such document, instrument or agreement, or replacement or predecessor thereto, as amended, modified and supplemented
from time to time and in effect at any given time. The words “hereof,” “herein” and “hereunder”
and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision
of this Agreement. The words “include” and “including” and words of similar import when used in this Agreement
shall not be construed to be limiting or exclusive.

 

17.         No
Oral Modification or Waivers. The terms herein may not be modified or waived orally, but only by an instrument in writing signed
by the party against which enforcement of the modification or waiver is sought.

 

18.         Attorney
Fees. In the event of any suit or action to enforce or interpret any provision of this Agreement or otherwise arising out of
this Agreement, the prevailing party is entitled to recover, in addition to other direct incremental costs, reasonable attorney
fees in connection with the suit, action, or arbitration, and in any appeals.

 

19.         Governing
Law; Jurisdiction; Venue. This Note, and all matters arising directly and indirectly herefrom, shall be governed in all respects
by the laws of the State of Nevada as such laws are applied to agreements between parties in Nevada.

 

20.         Entire
Agreement; Integration Clause. This Agreement sets forth the entire agreement and understandings of the parties hereto with
respect to this transaction, and this Agreement supersedes and nullifies all other agreements made between the parties hereto.

 

    	3 

     

    

  

21.         Counterparts.
This Agreement may be executed in as many counterpart copies as may be required. All counterparts shall collectively constitute
a single agreement.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	4 

     

    

  

SIGNATURE PAGE

 

IN WITNESS WHEREOF, each
of the parties has executed this Agreement respectively as of the date set forth below.

 

	BORROWER:	Creative Medical Technologies, Inc.
	 	 
	June 6, 2016	By 	/s/ Timothy Warbington
	 	 	Timothy Warbington, President
	 	 
	LENDER:	Creative Medical Health, Inc.
	 	 
	June 6, 2016	By 	/s/ Donald Dickerson
	 	 	Donald Dickerson, Chief Financial Officer

 

    	5 

     

    

  

Exhibit
1

[8% Promissory
Note]

 

See Attached

 

    	6Exhibit 10.2

  

THIS NOTE HAS NOT BEEN REGISTERED FOR SALE
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND SUCH LAWS AND THE RESPECTIVE RULES
AND REGULATIONS THEREUNDER.

 

Creative
Medical Technologies, Inc.

 

8% PROMISSORY NOTE

 

	$50,000.00	May 1, 2016

 

FOR VALUE RECEIVED,
Creative Medical Technologies, Inc., a Nevada corporation (the “Maker”), with a principal business office located
at 2007 W Peoria Avenue, Phoenix , Arizona 85029, hereby promises to pay to the order of CREATIVE MEDICAL HEALTH, INC., a Delaware
corporation, or any assignee of this Note who is registered as the owner of this Note by the Maker on a register maintained for
that purpose (hereafter referred to as the “Payee”), the principal sum of up to Fifty Thousand Dollars ($50,000.00),
based upon the aggregate principal amount of all Loan Advances owing to
the Payee by the Maker pursuant to the Loan Agreement dated as of May 1, 2016, between the Maker and the Payee (terms defined therein,
unless otherwise defined herein, being used herein as therein defined), together with interest accrued on the principal
amount outstanding from time to time after the date hereof. A permitted assignee of the Payee shall have the right to have a new
Note of like tender issued and registered in such assignee’s name upon surrender of this Note, endorsed for transfer to the
assignee.

 

The principal of this
Note, together with all interest then accrued on each Loan Advance, shall be payable on July 31, 2017 (the “Maturity Date”).
Simple interest on the principal amount outstanding of this Note shall be paid on the Maturity Date at the rate of 8% per annum.

 

The principal and interest
of this Note may be prepaid in whole or in part, without premium or penalty, at any time.

 

All principal and interest
payments hereunder are payable in lawful money of the United States of America to the Payee at the address first shown above, or
at such other address as may be directed by Payee, in immediately available funds.

 

The Maker hereby waives
presentment, demand, dishonor, protest, notice of protest, diligence, and any other notice or action otherwise required to be given
or taken under the law in connection with the delivery, acceptance, performance, default, enforcement or collection of this Note,
and expressly agrees that this Note, or any payment hereunder, may be extended, modified or subordinated (by forbearance or otherwise)
from time, without in any way affecting the liability of the Maker.

 

The Payee, at Payee’s
option, by written notice to the Maker, may declare the entire indebtedness evidenced by this Note immediately due and payable,
whereupon the same shall forthwith mature and become immediately due and payable without presentment, demand, protest or further
notice, in the event that the Maker shall fail to pay when due, any payment of principal or interest due hereunder and such failure
to pay is not cured within ten (10) days of the due date or upon the occurrence of one or more of the following events: (i) the
Maker commences a voluntary case under title 11 of the United States Code or the corresponding provisions of any successor laws;
(ii) anyone commences an involuntary case against the Maker under title 11 of the United States Code or the corresponding provisions
of any successor laws and either (a) the case is not dismissed by midnight at the end of the 60th day after commencement or
(b) the court before which the case is pending issues an order for relief or similar order approving the case; (iii) a court
of competent jurisdiction appoints, or the Maker makes an assignment of all or substantially all of its assets to, a custodian
(as that term is defined in title 11 of the United States Code or the corresponding provisions of any successor laws) for the Maker
or all or substantially all of its assets; and (iv) the Maker fails generally to pay its debts as they become due (unless those
debts are subject to a good-faith dispute as to liability or amount) or acknowledges in writing that it is unable to do so.

 

     

     

    

 

In the event that Maker
shall fail to pay when due any principal or interest payment, and the Payee shall exercise or endeavor to exercise any of its remedies
hereunder, the Maker shall pay all reasonable costs and expenses incurred in connection therewith, including, without limitation,
reasonable attorneys’ fees, and the Payee may take judgment for all such amount in addition to all other sums due hereunder.

 

No consent or waiver
by the Payee with respect to any action or failure to act by Maker which, without such consent or waiver, would constitute a breach
of any provision of this Note shall be valid and binding unless in writing and signed the Payee.

 

All agreements between
the Maker and the Payee are expressly limited to provide that in no contingency or event whatsoever, whether by reason of acceleration
of maturity of the indebtedness evidenced hereby or otherwise, shall the amount paid or agreed to be paid to the Payee for the
use, forbearance or detention of the indebtedness evidenced hereby exceed the maximum amount which the Payee is permitted to receive
under applicable law. If, from any circumstances whatsoever, fulfillment of any provision hereof, at the time performance of such
provision shall be due, shall involve transcending the limit of validity prescribed by law, then without the necessity of any action
by Payee or Maker, the obligation to be fulfilled automatically shall be reduced to the limit of such validity, and if from any
circumstance the Payee should ever receive as interest an amount which would exceed the highest lawful rate, such amount which
would be excessive interest shall be applied to the reduction of the principal balance hereof, and not to the payment of interest.
As used herein the term “applicable law” shall mean the law in effect as of the date hereof, provided, however, that
in the event there is a change in the law which result in a higher permissible rate of interest, then this Note shall be governed
by such new law as of its effective date. This provision shall control every other provision of all agreements between the Maker
and the Payee.

 

This Note shall be
governed and construed in accordance with the laws of the State of Nevada, except to the extent that such laws are superseded by
Federal enactments.

 

If any covenant or
other provision of the Note is invalid, illegal, or incapable of being enforced by reason of any rule of law or public policy,
all other covenants and provisions of the Note shall nevertheless remain in full force and effect, and no covenant or provision
shall be deemed dependent upon any other covenant or provision.

 

IN WITNESS WHEREOF,
the Maker, by its duly authorized officer, has executed this Note effective as of the date first above written.

 

	 	Creative Medical Technologies, Inc.
	 	 
	 	By:	/s/Timothy Warbington
	 	 	Timothy Warbington, CEO

 

    	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]